Amundi Purchases 83,460 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Amundi grew its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 556.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,450 shares of the company’s stock after acquiring an additional 83,460 shares during the period. Amundi’s holdings in Dr. Reddy’s Laboratories were worth $1,556,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of RDY. Robeco Institutional Asset Management B.V. raised its stake in shares of Dr. Reddy’s Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Fisher Asset Management LLC raised its stake in shares of Dr. Reddy’s Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock valued at $38,981,000 after acquiring an additional 1,977,419 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Dr. Reddy’s Laboratories by 400.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock valued at $8,373,000 after acquiring an additional 427,573 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Dr. Reddy’s Laboratories by 458.0% during the fourth quarter. Rhumbline Advisers now owns 430,062 shares of the company’s stock valued at $6,791,000 after acquiring an additional 352,994 shares during the last quarter. Finally, Artemis Investment Management LLP raised its stake in Dr. Reddy’s Laboratories by 398.3% in the fourth quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock worth $4,666,000 after buying an additional 236,224 shares in the last quarter. 3.85% of the stock is owned by institutional investors.

Analysts Set New Price Targets

RDY has been the subject of a number of research reports. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

Dr. Reddy’s Laboratories Price Performance

RDY stock opened at $13.23 on Tuesday. Dr. Reddy’s Laboratories Limited has a 1 year low of $12.50 and a 1 year high of $16.89. The company has a market cap of $11.04 billion, a P/E ratio of 21.06 and a beta of 0.48. The firm has a 50-day moving average of $13.83 and a 200 day moving average of $14.77. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, sell-side analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.